Sage Journals: Discover world-class research

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting 0.5–1% of the worldwide population. Whilst predominantly causing chronic pain and inflammation in synovial joints, it is also associated with significant extra-articular manifestations in a large proportion of patients. Among the various pulmonary manifestations, interstitial lung disease (ILD), a progressive fibrotic disease of the lung parenchyma, is the commonest and most important, contributing significantly to increased morbidity and mortality. The most frequent patterns of RA-associated ILD (RA-ILD) are usual interstitial pneumonia and nonspecific interstitial pneumonia. New insights during the past several years have highlighted the epidemiological impact of RA-ILD and have begun to identify factors contributing to its pathogenesis. Risk factors include smoking, male sex, human leukocyte antigen haplotype, rheumatoid factor and anticyclic citrullinated protein antibodies (ACPAs). Combined with clinical information, chest examination and pulmonary function testing, high-resolution computed tomography of the chest forms the basis of investigation and allows assessment of subtype and disease extent. The management of RA-ILD is a challenge. Several therapeutic agents have been suggested in the literature but as yet no large randomized controlled trials have been undertaken to guide clinical management. Therapy is further complicated by commonly prescribed drugs of proven articular benefit such as methotrexate, leflunomide (LEF) and anti-tumour necrosis factor α agents having been implicated in both ex novo occurrence and acceleration of existing ILD. Agents that offer promise include immunomodulators such as mycophenolate and rituximab as well as newly studied antifibrotic agents. In this review, we discuss the current literature to evaluate recommendations for the management of RA-ILD and discuss key gaps in our knowledge of this important disease.

Keywords

lungs joints fibrosis pulmonary rheumatoid arthritis therapy

Introduction

Interstitial lung disease (ILD) is a progressive fibrotic disease of the lung parenchyma. Occurring in association with several connective tissue diseases, it is the commonest and most important pulmonary manifestation of rheumatoid arthritis (RA) [Brown 2007; O’Dwyer et al. 2013]. RA-associated ILD (RA-ILD) may be a consequence of the chronic immune activation and inflammation that occurs in RA and which subsequently promotes aberrant fibroproliferation, or can be due to drug-related or infectious precipitants [O’Dwyer et al. 2013]. RA-ILD contributes significantly to decreased quality of life, progressive chronic disability, high utilization of healthcare resources and poorer mortality, with mean survival under 3 years [Kelly et al. 2014]. The management of ILD in patients with RA is a challenge. Several therapeutic agents have been suggested in the literature but as yet no large randomized controlled trials have been undertaken to guide clinical management. In this perspective, we discuss the current literature to evaluate recommendations for the management of RA-ILD and discuss key gaps in our knowledge of this important disease.

Histopathological and radiographic classification

RA-ILD has well described subtypes that are shared with the idiopathic interstitial pneumonias (IIPs). The four major histopathological and high-resolution computed tomography (HRCT) patterns of RA-ILD are shown in Table 1.

Table 1.

The four major histopathological and HRCT patterns of RA-ILD.

Subtype	Radiographic pattern	Histological pattern
Usual interstitial pneumonia	Bilateral subpleural and basal reticulation and honeycombing with or without traction bronchiectasis	Areas of advanced fibrosis next to normal lung as well as fibroblastic foci and microscopic honeycombing
Nonspecific interstitial pneumonia	Bilateral predominant ground glass opacities and the relative absence of honeycombing	Homogeneous cellular infiltrate, with variable degrees of uniform alveolar inflammation and interstitial fibrosis without the presence of honeycombing and lacking the more specific changes of UIP
Cryptogenic organizing pneumonia	Multifocal patchy areas of consolidation	Variable interstitial inflammation, intraluminal organization in alveolar ducts, occasionally alveoli and bronchioles with preservation of background lung tissues
Acute interstitial pneumonia/diffuse alveolar damage	Rapidly progressive patchy ground glass changes and basal consolidation	Acute diffuse alveolar damage with oedema and hyaline membranes

HRCT, high-resolution computed tomography; RA-ILD, rheumatoid arthritis interstitial lung disease; UIP, usual interstitial pneumonia.

The most common patterns found are usual interstitial pneumonia (UIP), accounting for 44–66% and nonspecific interstitial pneumonia (NSIP) (24–44%), followed by mixed disease (0–12%). Cryptogenic organizing pneumonia (COP) and acute interstitial pneumonia (AIP/diffuse alveolar damage (DAD)) are uncommon (0–11%), while lymphocytic interstitial pneumonia and desquamative interstitial pneumonia are rare [Tanaka et al. 2004; Lee et al. 2005; Yoshinouchi et al. 2005; Kelly et al. 2014].

A simple staging system for the extent of systemic sclerosis related ILD was proposed [Goh et al. 2008] and this has been shown to also correlate well with RA-ILD [Sathi et al. 2011]. Goh and colleagues’ system defines the extent of disease as limited if less than 20% of the lung parenchyma is affected and as extensive otherwise. Intermediate values (10–30%) are categorized by the forced vital capacity (FVC), with FVC values greater than 70% indicative of limited disease and vice versa [Goh et al. 2008].

Epidemiology

Incidence and prevalence

The reported prevalence of RA-ILD varies depending on the characteristics of the population selected, the definitions and criteria for diagnosis used, as well as the diagnostic tools employed. Prevalence has been reported in the range from 3.6% to 60% [Ayhan-Ardic et al. 2006; Bongartz et al. 2010; Richman et al. 2013; Kelly et al. 2014].

Annual incidence of RA-ILD is reportedly as high as 4.1 per 1000 people [Koduri et al. 2010]. The estimated lifetime risk of developing ILD for patients with RA is approximately 10% [Bongartz et al. 2010]. Interestingly, the incidence of other extra-articular manifestations (EAMs) for example vasculitis has decreased in the last decade but there has been an apparent increase in reported cases of RA-ILD [Bartels et al. 2010]. However, as O’Dwyer and colleagues argue, over the last decade improved clinical awareness of RA-ILD along with improved survival times (particularly as advancing years is a risk factor for its development) may have contributed to an increase in ILD incidence [O’Dwyer et al. 2013].

Mortality and prognosis

In addition to the increased mortality associated with RA itself, RA-ILD is a significant cause of mortality. The median survival of patients with untreated RA-ILD is approximately only 3 years [Bongartz et al. 2010; Koduri et al. 2010]. Compared with the general population, ILD accounts for 6–13% of the excess mortality of patients with RA and is the second most common cause of premature death after cardiovascular disease [Young et al. 2007; Bongartz et al. 2010]. The increased mortality can be mainly ascribed to respiratory failure due to ILD progression and infective complications of RA.

ILD associated with connective tissue diseases including RA purportedly has a lower mortality than idiopathic ILD [Agusti et al. 1992; Flaherty et al. 2003; Lee et al. 2005; Rajasekaran et al. 2006; Park et al. 2007; Song et al. 2013]. However, others have found no difference in prognosis [Hubbard and Venn, 2002; Kocheril et al. 2005; Kim et al. 2009, 2010; Bongartz et al. 2010]. These discrepancies may be a result of subtle undetected histologic differences, immunosuppressive RA drugs or the systemic effects of chronic autoimmune activation associated with RA [Cavagna et al. 2013].

The major determinants of prognosis appear to be RA-ILD subtype and disease extent. Studies have suggested UIP carries a worse outlook compared with NSIP, COP and overlap syndromes [Lee et al. 2005; Park et al. 2007; Kim et al. 2010; Nakamura et al. 2012; Kelly et al. 2013]. The acute DAD histological pattern has the highest mortality, with median survival time only 0.2 years [Tsuchiya et al. 2011]. More extensive fibrosis or worsening of the extent of disease on HRCT also appears to predict survival, with extensive disease (>20% of lung affected on HRCT) associated with twice the relative risk (RR) of dying compared with limited disease [Sathi et al. 2011; Kelly et al. 2013].

Pathogenesis

The aetiopathogenesis of RA-ILD remains as yet unclarified. Though RA itself is a risk factor for the development of fibrotic lung disease, only a subset of patients with RA develop ILD. A number of multifactorial components may contribute to RA-ILD development. Associated risk factors encompass environmental, serologic, clinical, genetic and drug related.

Demographic factors associated with developing ILD in RA include older age, male sex and longstanding disease [Gabbay et al. 1997; Bongartz et al. 2010; Koduri et al. 2010; Mori et al. 2012; Kelly et al. 2014]. Occupational exposure, for example silica inhalation, contributes to the development of ILD through chronic lung inflammation [Schwarz and King, 2010]. Other risk factors reported include high RA disease activity, high-grade functional impairment and the presence of other systemic features, for example articular erosions and rheumatoid nodules [Bongartz et al. 2010; Koduri et al. 2010; Habib et al. 2011].

A relationship between smoking and an increase in the prevalence of ILD has been identified in several studies [Gochuico et al. 2008; Kelly et al. 2014], with current or previous smoking history reported to confer an increased risk for ILD with an odds ratio (OR) of 3.8 for over 25 pack years [Saag et al. 1996]. However, other reports have found no association [Biederer et al. 2004]. A recent study of 356 patients with RA and pulmonary disease (ILD or airway disease) found the strong association observed in the univariate analysis between smoking history and ILD was not maintained after multinomial logistic regression analysis; this suggests factors other than smoking may trigger ILD occurrence in RA [Mori et al. 2012]. It is important to note RA-ILD can occur in nonsmokers [Ayhan-Ardic et al. 2006].

There is an association between positive rheumatoid factor (RF) and RA-ILD and evidence of a similar link with antibodies to cyclic citrullinated peptides (ACPA) has been found [Turesson et al. 2007; Inui et al. 2008; Aubart et al. 2011; Habib et al. 2011; Mori et al. 2012; Giles et al. 2014; Kelly et al. 2014; Yin et al. 2014; Doyle et al. 2015]. The association is inconsistent with some authors disputing these findings [Bongartz et al. 2007; Inui et al. 2008]; however a recent meta-analysis by Zhu and colleagues has concluded serum ACPA positivity is highly associated with the risk of RA-ILD and idiopathic pulmonary fibrosis among patients with RA, with an OR of 4.7 [95% confidence interval (CI) 2.071–10.572, p < 0.001) [Zhu et al. 2014].

The interaction between smoking, the lungs and RA is intriguing. Citrullinated proteins have been observed in lung tissue obtained from RA-ILD [Bongartz et al. 2007] and in the bronchoalveolar lavage (BAL) fluid of smokers but not in nonsmokers [Klareskog et al. 2006; Makrygiannakis et al. 2008]. Interestingly, both RF and ACPA have been detected in patients with ILD without clinical evidence of RA or to predate subsequent RA, particularly in smokers [Gizinski et al. 2009; Fischer et al. 2012].

This has led to the postulation that site-specific citrullination in the lungs leads to the generation of ACPA, which then promote immune dysregulation and lung abnormalities in patients with RA early in the rheumatoid process, especially in smokers. Cigarette smoke can potentially stimulate protein citrullination in the lung due to increased activity of pulmonary peptidylarginine deaminase, thus triggering human leukocyte antigen (HLA)-DR (shared epitope) restricted immune reactions to autoantigens. These data therefore suggest an aetiology involving an integration of environmental exposures, autoimmunity and genetic susceptibility may result in the development of not only ILD but also RA [Klareskog et al. 2006; Makrygiannakis et al. 2008; Chan et al. 2013]. Clearly, this is not the whole answer as RA-ILD can occur in nonsmokers [Ayhan-Ardic et al. 2006].

It appears likely that genetic predisposition plays a role. Michalski and colleagues observed patients with RA-ILD are more likely to possess specific α₁-antitrypsin variants, particularly non-M₁M₁ α₁-antitrypsin phenotypes [Michalski et al. 1986]. Several HLA alleles are associated with an increased susceptibility for RA-ILD, such as HLA-DR4, HLA-B40 and HLA-B54 [Charles et al. 1991; Sugiyama et al. 1994; Mori et al. 2012]; carriage of HLA-DRB1*1501 and *1502 alleles has been implicated with a RR ratio for RA-ILD of 4.02 (p = 0.013) [Migita et al. 2010; Mori et al. 2012]. Similarly, Furukawa and colleagues found DR2 serology (DRB1*15 and *16 alleles) appeared to impart increased risk for ILD in Japanese patients with RA, while HLA-DRB1 ‘shared epitope’ was associated with reduced risk [Furukawa et al. 2012]. However, these associations need to be confirmed by further studies.

Diagnosis

Diagnosis is based on clinical presentation, physical examination and investigations including sputum and blood tests, pulmonary function tests (PFTs), HRCT scan, occasionally BAL and more rarely a lung biopsy. Investigations are crucial for determining the type and severity of lung disease and its change over time. Specific subtypes of IIP have significantly different prognoses and treatment associated with them and therefore an accurate diagnosis is extremely important for optimum management; however the relevance of determining the subtype in selecting therapy for patients with RA-ILD is still to be determined.

Clinical presentation

Whilst some patients with RA-ILD can be asymptomatic, the majority present with progressive exertional dyspnoea, usually with an associated dry cough. On examination, tachypnoea and fine bibasal chest crackles are often evident, with finger clubbing a relative rarity.

Pulmonary function tests

PFTs are a sensitive but relatively nonspecific measure of RA-ILD. The majority of patients with ILD demonstrate physiological abnormalities in both lung volumes and gas transfer, namely a restrictive defect with low total lung capacity (TLC) and low forced vital capacity (FVC), low transfer factor of the lung for carbon monoxide (TLCO) and oxygen desaturation at rest or on exertion [American Thoracic Society/European Respiratory Society, 2002]. Decreased TLCO is reported to be the most sensitive test for predicting the presence of ILD, as well as the extent of disease [Dawson et al. 2001; Hamblin and Horton, 2011]. TLCO also has prognostic value with a low TLCO (<54% of the expected value) predictive of disease progression [Dawson et al. 2002]. However, a recent study comparing baseline vital capacity (VC) and TLCO at presentation with RA-ILD in extensive versus limited disease found that baseline VC was relatively maintained in limited disease but significantly reduced in patients with extensive disease whilst TLCO was reduced in both limited and extensive disease; therefore lung volumes may have greater utility than gas transfer in calculating disease extent at baseline [Chan et al. 2013; Kelly et al. 2013]. In interstitial pulmonary fibrosis (IPF), worsening desaturation (< 88%) is also associated with a poorer prognosis and is useful for guiding oxygen therapy and transplantation [Wells and Ward, 2014]. It should be noted that both TLCO and desaturation with walking can be influenced by the coexistence of emphysema or pulmonary hypertension [Wells and Ward, 2014].

Importantly, PFTs are very valuable for monitoring disease change over time, especially as it is safer and more sensitive than repeat HRCT. Patients with progressive decline in lung volume or gas transfer are likely to have worsening disease while patients with static disease will have correspondingly stable test results. Recommendations for monitoring are 3–6 monthly, then every 6–12 months if stable. Suggested parameters for significant decline are a 15% decrease in carbon monoxide diffusion factor (DLCO) and 10% decrease in FVC from baseline values [American Thoracic Society/European Respiratory Society, 2002].

Bronchoalveolar lavage

BAL is not routinely used as BAL patterns are relatively nonspecific. However, BAL may be a useful adjunct to clinical and radiographic evaluation for patients who lack an assured UIP pattern on thoracic HRCT. BAL fluid in patients with RA-ILD shows predominantly inflammatory cytology with increased lymphocytes, eosinophils, macrophages and neutrophils [Lee et al. 2005]. The results of BAL analysis may have a modest ability to distinguish between different subtypes of RA-ILD; a slight neutrophilia (>4%) may be more frequent in UIP while lymphocytosis (>18%) is more common in NSIP and organising pneumonia (OP) [Cavagna et al. 2013]. BAL results may also have prognostic implications as neutrophilia is linked to more advanced disease and attenuated therapeutic response [Cavagna et al. 2013]. BAL can perhaps be most usefully employed in excluding infectious processes or differential diagnoses such as sarcoidosis.

Imaging

HRCT has become the standard noninvasive method of diagnosing and defining ILD in patients with RA. In the setting of IPF, the diagnostic accuracy of HRCT compared with histological diagnosis for UIP and NSIP has been reported to be approximately 70% in various studies; disagreement occurs in up to one third of cases, particularly in NSIP which can have a varying radiological picture [Sharyn et al. 2001; Flaherty et al. 2003; Silva et al. 2008], in which case surgical lung biopsy (SLB) may be necessary to reach an accurate diagnosis [Johkoh et al. 1999; Raghu et al. 1991; Hunninghake et al. 2001; Sharyn et al. 2001; Flaherty et al. 2003; Mink and Maycher, 2012; American Thoracic Society, 2002]. The predominant feature of honeycombing on HRCT yields a specificity of approximately 95% and sensitivity of approximately 40% for UIP; whereas a predominance of ground glass opacities gives a sensitivity of approximately 95% and specificity of approximately 40% for NSIP [Mink and Maycher, 2012].

Studies have suggested these findings for IPF are similar in RA-ILD, with a high level of correlation between HRCT features and underlying histopathological pattern of UIP [Tanaka et al. 2004; Lee et al. 2005; Kim et al. 2009; Assayag et al. 2014]. With typical HRCT findings, UIP can be diagnosed without SLB among patients with RA-ILD as in IPF [Lee et al. 2005]. However, as with IPF [Sharyn et al. 2001], HRCT findings of the NSIP pattern can be diverse in RA [Lee et al. 2005], therefore SLB may be helpful for diagnosis when the HRCT findings are not typical for UIP. However, larger studies assessing the correlation between HRCT and histopathological patterns of RA-ILD are needed as studies to date have been small. HRCT patterns of common RA-ILD subtypes are outlined in Table 1.

Other imaging modalities, for example radioisotope scans, have no utility. Plain chest radiography can reveal reticular and fine nodular opacities in the lower zones but it has a low sensitivity and can be normal until relatively advanced [Cavagna et al. 2013]. Old HRCTs and X-rays (including abdominal films, the upper slices of which may have encompassed lung bases) can be very helpful in assessing duration of disease [Lake and Proudman, 2014].

Lung biopsy

Surgical lung biopsy is the gold standard for establishing a histopathological diagnosis. However, due to the potential risks associated, most patients are diagnosed without pathological confirmation. As discussed above, HRCT imaging has a high level of correlation with histopathological features of UIP, thus unless the HRCT findings are indeterminate, a biopsy is rarely undertaken.

If a biopsy is undertaken, the preferred option is video-assisted thoracoscopic surgery rather than open-lung biopsy [Cavagna et al. 2013]. Transbronchial biopsies are inadequate for diagnosis with the exception of diagnosing COP, AIP or fungal infection [American Thoracic Society/European Respiratory Society, 2002].

Ultrasound

In addition to standard radiological examination with HRCT, ultrasound of the lung could provide an inexpensive, safe, noninvasive and radiation-free tool for screening for and monitoring nascent structural changes. Corroborating findings of studies in other connective tissue disease (CTD) [Sperandeo et al. 2009; Delle Sedie et al. 2010; Tardella et al. 2012; Barskova et al. 2013], recent research demonstrates lung sonography, either with standard or pocket-size devices, has a high sensitivity (92–100%) and specificity (55–56%) for detecting underlying ILD in patients with RA as determined by HRCT [Cogliati et al. 2014; Moazedi-Fuerst et al. 2014, 2015].

Differential diagnosis

Patients with RA with onset of acute respiratory symptoms may have AIP, an exacerbation of preexisting ILD (either known or previously unknown), infection (particularly as many RA drugs lead to immunosuppression), pulmonary embolism, a drug reaction or a combination of any of these.

It is now well recognized that ILD can be the presenting feature of RA in up to 10% of cases [Chan et al. 2013], therefore patients presenting with an IIP should be investigated for an underlying occult CTD, particularly RA. However, ILD more often arises in patients with established long-term RA [Chan et al. 2013]. It is important to distinguish between primary ILD and secondary diffuse lung disease as a result of indirect complications. Such complications include iatrogenic, for example adverse effects of disease-modifying anti-rheumatic drugs (DMARDs), infection and lymphoproliferative disease.

The ability to distinguish between primary RA-ILD and secondary or indirect complications can be challenging and is principally based on clinician judgment, clinical context, a temporal link of disease development with a particular therapy and response to withdrawal of the suspected agent [Doyle et al. 2014].

Biomarkers

Standardized algorithms for identification of patients with RA at risk of developing clinically significant ILD are lacking. Therefore, discovering unique markers of RA-ILD that can contribute to disease detection could have a significant impact.

Alongside clinical risk factors including age, male sex and smoking history, investigators have attempted to identify serologic proteins associated with RA-ILD. With available evidence suggesting a key role for dysregulated B-cell immunity and citrullinated proteins, the possibility that ACPA might therefore predict the later development of ILD in patients with RA, particularly active smokers, merits consideration. Zhu and colleagues have reported serum ACPA positivity is highly associated with the risk of RA-ILD with an OR of 4.7 (95% CI 2.071–10.572, p < 0.001) [Zhu et al. 2014].

Heat shock proteins can distinguish RA-ILD from RA without ILD with a sensitivity and specificity of 29% and 96% respectively [Harlow et al. 2013]. In CTD-ILD a range of surfactant proteins and cytokines have been identified [Bonella and Costabel, 2014]; increased matrix metalloproteinases have been shown to correlate with IPF [Rosas et al. 2008]. These could all have relevance to RA-ILD [Doyle et al. 2015; Chen et al. 2015]. Other markers of potential relevance for ILD include Krebs von den Lungen 6 [Kinoshita et al. 2004], cytokine and metalloproteinase (MMP) [Oka et al. 2013] and platelet-derived growth factor [Gochuico et al. 2008]. None of these have yet been shown to be of clinical value.

A large UK collaborative study is currently ongoing to assess the potential prognostic value of serological and genetic markers in patients with RA-ILD, CTD-ILD and IIP. It is anticipated that the results will guide subsequent therapeutic trials in patients with IIP (personal communication).

Treatment

The treatment of RA-ILD can be divided into supportive measures and treatment against the inflammatory processes that are putatively responsible for its pathogenesis. To date, there is no specific treatment and combined with the lack of robust evidence to support recommendations, there is no contemporary consensus for the treatment of RA ILD. We evaluate the best available evidence to inform a treatment rationale.

Conservative therapy

For patients with mild disease or contraindications to pharmacological treatments, for example multiple comorbidity, advanced age or frailty, conservative treatment may be advisable. Nonpharmacological treatment may encompass education, psychosocial support and exercise rehabilitation.

The potential of pulmonary rehabilitation in RA-ILD is as yet undefined, but it has shown beneficial short-term effects on dyspnoea, functional exercise capacity and quality of life in IPF [Wells and Hirani, 2008; O’Dwyer et al. 2013]. However, the utility of pulmonary rehabilitation in RA is likely to be limited due to the functional limits articular disease can impose on patients [O’Dwyer et al. 2013]. Consideration may need to be given to the development of RA-specific pulmonary rehabilitation protocols.

With cigarette smoke implicated in not only the pathogenesis of RA-ILD, but also in inducing and worsening both the severity of articular disease and lung damage, encouraging and supporting patients with RA-ILD who smoke in quitting should be a priority. Smoking cessation counselling and support as well as nicotine replacement therapy should be available for all patients with RA.

Supplemental oxygen therapy can be important in attenuating severe symptoms in palliative disease, though its effect on the disease course, if any, remains uncertain [O’Dwyer et al. 2013]. Appropriate treatment for acute and coexisting infections should be given. Finally, annual influenza vaccination and regular pneumococcal vaccination are recommended for all patients with RA-ILD, particularly as RA treatment utilizes many immunosuppressive drugs.

Immunosuppressive agents

Traditionally treatment initiated for RA-ILD was empirical and typically corticosteroids were used as first-line agents based on limited evidence from the IIPs, often with highly variable results. Certain ILD subtypes, in particular NSIP and OP, can be steroid responsive and may be managed with aggressive corticosteroid therapy and frequent follow up [O’Dwyer et al. 2013]. Patients who responded to steroids often had immunosuppressive drugs such as azathioprine added, again based on evidence from IPF when it was felt that steroids and azathioprine resulted in improved survival compared with steroids alone [Raghu et al. 1991]. However, the recent PANTHER-IPF study (Prednisone, Azathioprine, N-acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis) contradicted this protocol, having been prematurely terminated as a consequence of increased morbidity and mortality among the azathioprine and prednisone treatment arm [The Idiopathic Pulmonary Fibrosis Clinical Research Network, 2014]. Much of the excess mortality was due to pulmonary infection; it is estimated that corticosteroids increase the risk of serious infection fourfold [Dixon et al. 2012]. The mechanism for this is uncertain but may relate to the observation that modest doses of steroid drop immunoglobulin G levels which may precipitate infection in RA, especially in patients treated with biologics. Corticosteroids may be combined with other immunosuppressive agents such as cyclosporine and cyclophosphamide. However, there is a lack of evidence from controlled studies regarding their efficacy in RA-ILD and recommendations are often extrapolated from IPF and other CTD-associated ILDs.

The roles of free radical scavenger N-acetylcysteine and low-dose warfarin, both of which initially showed promise in IPF [Demedts et al. 2005; Kubo et al. 2005], have also been challenged as a result of recent disappointing trial results [Noth et al. 2012; Raghu et al. 2012].

Cyclophosphamide is an immunosuppressive drug commonly used to treat patients with ILD. However, studies have shown no benefit of cyclophosphamide in IPF and although initially it was thought to have benefit in systemic sclerosis ILD (SSc-ILD) [Tashkin et al. 2006, 2007], a 2008 meta-analysis concluded cyclophosphamide treatment did not result in a clinically significant improvement of pulmonary function (PF) in patients with SSc-ILD [Nannini et al. 2008]. However, when combined with methylprednisolone pulses, cyclophosphamide therapy has demonstrated some modest success in patients with systemic sclerosis associated pulmonary disease, stabilizing or improving lung function parameters [Airo et al. 2007; Yiannopoulos et al. 2007]. No randomized control trial has been performed for its use in RA-ILD but it is utilized in extensive UIP in RA, albeit with limited efficacy data [Chan et al. 2013]. Cyclophosphamide may be useful in extensive or rapidly progressive ILD with high inflammatory activity [Chan et al. 2013] and also have a role in the treatment of steroid-unresponsive suspected drug-induced pneumonitis [Suwa et al. 1998].

Mycophenolate mofetil is an immunosuppressive agent that has potential utility given its additional action on nonimmune cells such as fibroblasts, endothelial cells and smooth muscle cells. Mycophenolate has been shown to stabilize or improve PF in CTD-ILD, mainly scleroderma [Swigris et al. 2006; Tzouvelekis et al. 2012; Fischer et al. 2013]. A meta-analysis of mycophenolate in SSc-ILD demonstrated it had potential for disease stabilization, preventing further FVC decline [Tzouvelekis et al. 2012]. Studies in a mixed CTD cohort with a small number of patients with RA-ILD found mycophenolate helped patients achieve symptomatic improvement and stabilization or improvement in PFTs and imaging, as well as significant tapering of steroids [Saketkoo and Espinoza, 2008; 2009]. Some authors advocate mycophenolate as a first-line agent over cyclophosphamide or a maintenance therapy after cyclophosphamide therapy [Saketkoo and Espinoza, 2009]. However, these data are preliminary and there are no controlled studies directly comparing cyclophosphamide and mycophenolate in ILD-RA. In the treatment of RA-ILD, it appears to be effective at doses of 1–2 g per day in patients with early or limited disease [Swigris et al. 2006; Kelly and Saravanan, 2008; Saketkoo and Espinoza, 2008]; however, it does not appear to be entirely effective in ameliorating the articular manifestations of the disease, necessitating concomitant DMARD prescription [Kelly and Saravanan, 2008]. Overall mycophenolate appears to combine reasonable efficacy with relatively low toxicity, conferring a modest improvement in lung function, although stabilization of lung function is a more typical response. However, the published evidence for its use in RA-ILD remains very small, though existing studies do provide supportive evidence to justify larger clinical trials.

Disease-modifying antirheumatic drugs

The treatment of RA-ILD is complicated due to the majority of traditional DMARDs of proven articular benefit having been implicated in the development of drug-related pneumonitis or accelerated respiratory failure in the setting of existing ILD. The nonbiologic DMARDs most frequently linked to ILD-promoting effects (of which the most common manifestation is acute interstitial hypersensitivity pneumonitis) are methotrexate (MTX) and LEF.

The recommended first-line DMARD for RA [National Institute for Health and Care Excellence, 2009], MTX is known to confer an increased risk of pneumonitis, with a recent meta-analysis by Conway and colleagues discovering a RR of 7.81 (95% CI 1.76−34.72) [Conway et al. 2014]. While relatively rare, affecting between 0.43% and 1% of treated patients [Salliot and Van Der Heijde, 2009; Sathi et al. 2012], it has a mortality rate of around 20% [Chikura et al. 2008]. Patients with reduced baseline PF are at increased risk and are most likely to develop it within the first 6 months of therapy [Chikura et al. 2008; Sathi et al. 2012]. Hence baseline PF tests are advised. Importantly MTX has not been conclusively shown to induce or exacerbate underlying RA-ILD [Gaffo and Alarcón, 2008; Bongartz et al. 2010] or lead to a greater risk of pulmonary death than patients not taking MTX [Conway et al. 2014]. However, the increased risk of pneumonitis means that it may be prudent to avoid first-line use of MTX in patients with a previous diagnosis of ILD. In those patients with RA who develop acute or subacute breathlessness within 6 months of commencing MTX, we recommend suspension of therapy and repeat PF tests. If these show a reduction of more than 10% from baseline values, HRCT of the chest is recommended to help define whether pneumonitis has occurred. Folinic acid rescue therapy with high-dose steroids should be initiated in these cases.

Similarly, LEF has been reported to have associations with potentially fatal rapid onset pneumonitis and ILD [Kamata et al. 2004; Savage et al. 2006; Martin et al. 2007; Inokuma, 2011]. With regards to ILD, approximately 1% of patients treated with LEF develop new or worsening ILD [Hyeon Ju et al. 2007; Sawada et al. 2009] and patients treated with LEF have an almost twofold increase in risk of ILD compared with those not receiving LEF [Suissa et al. 2006]. However, there is no excess risk of developing LEF-induced ILD unless there is history of ILD or MTX use [Suissa et al. 2006].

The main pathogenetic mechanism of both MTX- and LEF-induced pneumonitis is attributed to hypersensitivity reactions, particularly in the case of established lung disease. Susceptibility is linked to genetic factors. The HLA-A*31:01 allele has recently been reported to be a possible predictor of MTX-induced ILD in Japanese patients [Furukawa et al. 2013]. The prevalence of this particular genetic subset in the Japanese population is more than double that in the white population (8.7% versus 3.9%), possibly explaining the increased risk of this drug side effect in Japan [Furukawa et al. 2013]. Similarly, LEF-associated pneumonitis appears to occur much more frequently in specific ethnic populations (namely Japanese and Korean) [Hyeon Ju et al. 200; Sawada et al. 2009], whereas in Western populations pneumonitis only occurs as a complication of LEF therapy at a rate of less than 0.1% [Chan et al. 2013; Roubille and Haraoui, 2014].

Biologic drugs

Antitumour necrosis factor agents

Antitumour necrosis factor (anti-TNF) agents have shown great efficacy in improving symptoms and articular disease progression. However, their expanding use has led to concern regarding potential pulmonary toxicity. New-onset or exacerbation of existing ILD has been reported following the use of all anti-TNF agents approved for RA: infliximab [Mori et al. 2006; Ostor et al. 2006; Takeuchi et al. 2008; Taki et al. 2009], etanercept [Lindsay et al. 2006; Hagiwara et al. 2007; Tournadre et al. 2008; Koike et al. 2009] and adalimumab [Schoe et al. 2006; Dascalu et al. 2010; Yamazaki et al. 2010; Koike et al. 2012; Dias et al. 2014], as well as newer agents certolizumab [Pearce et al. 2012; Glaspole et al. 2013; Lager et al. 2013] and golimumab [Hadjinicolaou et al. 2011].

In a case series of 226 patients taking anti-TNF agents (of whom 83% had RA), the authors observed that 10% of patients developed ILD after initiation of anti-TNF therapy [Ramos-Casals et al. 2007]. Another review in 2011 declared 144 cases of new onset or exacerbations of ILD reported to date in patients with RA treated with anti-TNFs [Panopoulos and Sfikakis, 2011]. In a retrospective study of 122 patients, 89% of whom had RA, Perez-Alvarez and colleagues found worsening or new ILD developing after commencement of anti-TNF agents [Perez-Alvarez et al. 2011]. Nakashita and colleagues’ study of 163 patients with (n = 58) or without established ILD (n = 105) found anti-TNF drug treatment, but not tocilizumab or abatacept, resulted in risk of emergence or progression of ILD, particularly for patients with prexisting ILD [Nakashita et al. 2014]. Strikingly, anti-TNF-induced ILD tends to be rapidly progressive and often fatal with a high mortality of one third of patients, rising to two thirds in those with preexisting ILD [Ramos-Casals et al. 2007; Perez-Alvarez et al. 2011; Roubille and Haraoui, 2014]. It has been recommended that patients with pre-existing RA-ILD receive anti-TNF treatment with caution. Other risk factors for death include older age (>65 years), later onset of ILD and greater immunosuppression [Perez-Alvarez et al. 2011].

With around one third of patients receiving concomitant MTX it has been questioned whether the effect is due to anti-TNF potentiation of the pulmonary toxicity of MTX; however available data argue in favour of an independent and specific potential pulmonary toxicity of anti-TNF drugs [Roubille and Haraoui, 2014].

In contrast, other studies argue against any association between anti-TNF and ILD in RA. A 2010 report from the British Society for Rheumatology Biologics Register on patients with RA-ILD taking either anti-TNF agents or traditional DMARDs found no difference in mortality [Dixon et al. 2010]. However, death from RA-ILD was higher in patients treated with anti-TNF therapy (21%) compared with those on DMARDs (7%), although reporting bias may have contributed [Dixon et al. 2010]. Herrinton and colleagues’ cohort study of over 8000 patients with RA found no evidence that anti-TNF therapy was associated with ILD compared with nonbiologic therapies [Herrinton et al. 2013], though this excluded subjects with preexisting pulmonary disease, therefore a potential role in exacerbation cannot be excluded. Jani and colleagues’ recent systematic review cautioned vigilance, concluding that although a clinically meaningful increased risk of poor prognosis with anti-TNF agents could not be clearly established yet neither could it be excluded [Jani et al. 2014].

However, anti-TNF drugs have also shown potential for pulmonary disease stabilization or improvement [Vassallo et al. 2002; Bargagli et al. 2004; Antoniou et al. 2007; Wang et al. 2011; Horai et al. 2012]. Experimental studies show TNFα may have both profibrotic and antifibrotic effects, suggesting an imbalance between these two roles may either trigger fibrosis or conversely stabilize existing ILD in predisposed individuals, though further work is needed to confirm this hypothesis [Roubille and Haraoui, 2014; Olivas-Flores et al. 2015]. The paradoxical effects of anti-TNF have been highlighted by a report from Komiya and colleagues where adalimumab therapy simultaneously improved RA-associated lung disease and was implicated in the development of drug-induced interstitial disease [Komiya et al. 2011].

Rituximab

Rituximab (RTX) is a monoclonal antibody against the B-cell marker CD20, licensed for the treatment of RA in anti-TNF nonresponders. The demonstration of follicular B-cell hyperplasia and interstitial plasma cell infiltrates in patients with RA-ILD has suggested potential B-cell involvement in its pathogenesis and increased interest in the use of RTX for this indication [Atkins et al. 2006].

The safety and efficacy of RTX are currently under investigation for patients with RA-ILD but studies have been small and results inconclusive. Four small observational studies assessing the safety of RTX in patients with RA with concomitant ILD suggested it was relatively safe and did not lead to progression of ILD [Dass et al. 2011; Becerra and Cambridge, 2013; Romero et al. 2013; Kabia et al. 2015]; it also showed some success as a rescue therapy for severe RA-ILD [Braun-Moscovici et al. 2013] and in an isolated case report [Hartung et al. 2012]. Conversely one 48-week study assessing the efficacy and safety of two courses of RTX in in a small number of patients with progressive RA-ILD did not find any consistent improvement [Matteson et al. 2012]. Data from the British rheumatoid interstitial lung (BRILL) network has been amalgamated with that from the BSRBR database to allow comparison of patients with RA-ILD receiving RTX versus anti-TNF therapy as first-line biologic treatment. Analysis shows significant survival advantages for those treated with RTX (personal communication).

RTX has shown promise in ILD associated with other CTD, such as scleroderma and systemic lupus erythematosus, with improvement or stabilization of lung function [McGonagle et al. 2008; Daoussis et al. 2010, 2012; Haroon et al. 2011; Yoo, 2012; Sumida et al. 2014; Bosello et al. 2015]. However, studies are again either small or single case reports and some reporting bias may exist.

As with other biologic therapies, there have been concerns about potential pulmonary toxicity with RTX. Identified cases come largely from lymphoproliferative disorders [Lioté et al. 2010] but there are a few reports in patients with RA [Soubrier et al. 2008; Panopoulos and Sfikakis, 2011]. RTX-associated ILD is reportedly rare, with estimated incidence of 0.01–0.03% [Hadjinicolaou et al. 2012].

Robust clinical trials are urgently necessary to inform decision making in the use of RTX for this indication. Current ongoing trials include comparing RTX with cyclophosphamide in CTD-ILD [ClinicalTrials.gov identifier: NCT01862926]; RTX for IPF [ClinicalTrials.gov identifier: NCT01969409] and a phase I/II trial assessing the combination of RTX, plasma exchanges and corticosteroids in patients with acute exacerbations of IPF [ClinicalTrials.gov identifier: NCT01266317].

Other agents

There is a paucity of data regarding newer biological therapies such as the T-cell costimulation blocker abatacept or interleukin 6 (IL-6) receptor monoclonal antibody tocilizumab. Apart from one case study of possible deterioration of RA-related ILD after the administration of abatacept (which also had other confounding factors that may account for this occurrence) [Wada et al. 2012], abatacept has not been shown to have any noninfectious pulmonary toxicity [Hadjinicolaou et al. 2011] though Jani and colleagues suggest current data are insufficient to draw firm conclusions [Jani et al. 2014]. There are also few data with regards to efficacy, apart from a small observational study of four patients which demonstrated no adverse pulmonary effects and no deterioration in lung function over the course of treatment [Mera-Varela and Perez-Pampin, 2014]. A single case report showed improvement of RA-ILD with tocilizumab [Mohr and Jacobi, 2011] whereas others have noted ILD occurrence or exacerbation following tocilizumab use [Hadjinicolaou et al. 2011; Wendling et al. 2013; Jani et al. 2014; Roubille and Haraoui, 2014] including one fatality [Kawashiri et al. 2012].

The IL-1 receptor antagonist anakinra has no literature indicative of noninfective pulmonary complications with its use [Roubille and Haraoui, 2014] but also little to suggest potential therapeutic benefit or a potential role in ILD. Contemporary interest has been directed on a final category of biologic agent, the tyrosine kinase inhibitors (TKIs), which already have an established role in oncology. Recent clinical trials have demonstrated encouraging results with a TKI (nintedanib) in IPF [Richeldi et al. 2011, 2014; Mazzei et al. 2015]. Imatinib however has failed to show efficacy in small studies in IPF [Daniels et al. 2010] and SSc-ILD [Khanna et al. 2011]. Similarly, one small study examining imatinib in combination with cyclophosphamide for the treatment of SSc-ILD found only equivocal results [Sabnani et al. 2009]. It is uncertain whether these findings can be extrapolated to the arena of RA-ILD but there is certainly currently no literature to support a possible therapeutic role. Second, experiences in oncology have found TKIs are associated with potentially severe or fatal ILD, particularly in patients with preexisting pulmonary fibrosis [Min et al. 2011]. Greater understanding of the pathogenetic mechanisms underlying RA-ILD may lead to more targeted and informed use of these agents with potential for future therapeutic benefit.

Pirfenidone, a relatively novel antifibrotic and anti-inflammatory agent, has demonstrated efficacy in IPF [Cottin, 2013; Richeldi, 2013; King et al. 2014; Xaubet et al. 2014] and has been approved by the National Institute for Health and Care Excellence for the management of patients with IPF [National Institute of Health and Clinical Excellence, 2013]. Its role in CTD-related ILD has only been explored in small-scale studies in SSc-ILD, which have demonstrated modest success [Nagai et al. 2002; Miura et al. 2014; Udwadia et al. 2015]. It remains unexplored in RA-ILD, though there is a biologically plausible mechanism for its efficacy in this area. Pirfenidone acts by regulating the profibrotic cytokine transforming growth factor (TGF)-β, thus impeding the fibrotic process and therefore it is possible the drug could act in any fibrotic ILD in which TGF-β convincingly contributes to pathology [Dhooria et al. 2015]. Thus there is a strong justification to evaluate the efficacy of pirfenidone in the fibrotic NSIP pattern and the fibrotic stage of other subtypes [Dhooria et al. 2015]. Conversely, pirfenidone is unlikely to be of benefit in cellular NSIP, COP and other ILDs with preeminent cellular inflammation where steroids or immunosuppressive agents have greater rationale [Dhooria et al. 2015]. However, this theory remains strictly hypothetical at present, so there is a strong need for robust randomized controlled trials in RA-ILD. However, a pragmatic further consideration is expense; with cost of the drug prohibitively high it is unlikely to be a feasible therapeutic option in the near future.

Finally bosentan is an endothelin receptor antagonist, used for pulmonary arterial hypertension, but which has recently raised interest for its potential role in fibrosis [Clozel and Salloukh, 2005]. There is a very limited amount of literature on its use for IPF and CTD-ILD. Earlier promise in IPF was not sustained in later trials [King et al. 2008, 2011]. Most of the data regarding bosentan’s effects on CTD-ILD are derived from patients with SSc. A 12-month prospective, double-blind, randomized, placebo-controlled, parallel group study of 163 patients with SSc-ILD did not support the use of bosentan [Seibold et al. 2010] and similarly, neither did a 24-month prospective open-label study involving nine patients with SSc-ILD ineligible for cyclophosphamide [Furuya and Kuwana, 2011]. Bosentan has not been shown to affect progression of SSc-ILD [Legg, 2010]. New studies evaluating bosentan in RA-ILD are required to draw firm conclusions.

Lung transplant

For younger patients with advanced refractory disease, the option of single lung transplantation should be considered. However, published outcome data for lung transplant in CTD-associated ILD are limited. A recent systematic review of scleroderma-associated ILD noted overall 3-year survival from 67% to 83% and 5-year survival from 46% to 76% [Richardson and Singer, 2014]. Patients with SSc-ILD have demonstrated similar survival rates following lung transplantation compared with patients with IPF or idiopathic pulmonary arterial hypertension [Schachna et al. 2006]. There are few studies evaluating outcomes in patients with RA-ILD who underwent lung transplantation. A retrospective study of survival in 10 patients with RA-ILD who received a lung transplant compared with 53 patients with IPF and 17 with SSc-ILD reported similar survival rates in RA-ILD compared with IPF (67% versus 69% respectively), albeit with higher survival rate in SSc-ILD (82%) [Yazdani et al. 2014]. Nevertheless the suggestion that patients with RA-ILD have outcomes comparable with other transplanted patient groups is reassuring. Lung transplantation may be most effective in patients under the age of 60 years without any significant comorbidity and good functional ability and exercise tolerance. Referral to transplant should occur prior to oxygen dependence [Kelly and Saravanan, 2008]. Ideally, pharmacological and oxygen intervention should be decided with joint respiratory and rheumatology input [Kelly and Saravanan, 2008]. Lung transplantation may be contraindicated because of age, immobility EAM and comorbidities such as osteoporosis. For such patients, active palliation may be introduced. Palliative measures include supplementary oxygen therapy and treatment of cough, gastro-oesophageal reflux and breathlessness [Lake and Proudman, 2014].

Future directions

Three main areas of importance have been identified for current and future translational research to focus on: subclinical RA-ILD, radiographic/histopathologic subtyping and biomarker discovery [Doyle et al. 2014]. Approximately one third of patients with RA will have evidence of subclinical ILD with a substantial minority progressing to clinically evident RA-ILD over time [Gochuico et al. 2008]. A better understanding of the clinical significance of subclinical RA-ILD as well as risk factors for its progression to clinically evident disease could allow targeted preventative interventions to be undertaken and management of progressive subclinical disease [Doyle et al. 2014]. Better knowledge of the subtypes of RA-ILD as well as their similarities and differences to IPF could improve treatment and prognostic knowledge, as well as rationalize exploration of biologic mechanisms and drugs that have been previously identified in IPF [Doyle et al. 2014]. Accurate and clinically practical biomarkers could allow prediction of individuals at high risk for future or progressive RA-ILD, enabling earlier diagnosis and treatment, as well as disease monitoring and measuring therapeutic response. Biomarkers could also help differentiate between primary and secondary RA-ILD and provide surrogate end points for clinical trials [Doyle et al. 2014].

Current work showing promise includes RA and ILD genome-wide association studies, which could help us acquire knowledge about the genetics of RA and ILD, thereby potentially providing insight into disease pathogenesis and guiding drug discovery as well as allowing genetic markers of susceptibility to RA-ILD to be identified [Stahl et al. 2010; Eyre et al. 2012; Fingerlin et al. 2013; Okada et al. 2014; Spagnolo et al. 2014]. Proteomic analysis of BAL fluid from patients with RA-ILD has been able to distinguish between various RA-ILD subtypes [Kozo et al. 2013]; future applications of proteomics may include clinical diagnostic tools or risk prediction. Ytterberg and colleagues have identified similar citrullinated peptides in the bronchial and synovial tissue of patients with RA which could potentially lead to new therapeutic targets [Ytterberg et al. 2014]. With regards to imaging, 18F-fluorodeoxyglucose positron emission tomography or CT could be useful in future for identifying early ILD changes [Olivas-Flores et al. 2015].

Conclusion

RA-ILD is an increasingly recognized and common complication that contributes significantly to overall morbidity and mortality in RA, yet is still relatively poorly understood. Multidisciplinary management incorporating rheumatologists and respiratory specialists has a vital role in optimizing the care of these patients. We have summarized the current state of knowledge in RA-ILD. Current and future translational research should focus on improving awareness of the natural history and clarify the aetiopathogenetic cascade underlying the occurrence of RA-ILD, in order to design focused therapies, which are essential to both optimize the therapeutic approach of RA-ILD and to minimize the risk of its development in potentially predisposed patients.

Currently, distinct clinical subtypes of RA-ILD are recognized; efforts to elucidate if they differ in terms of prognosis and therapeutic response should be made in order to stratify treatment effectively. Evidence of the effectiveness of recently identified therapeutic agents is based on observational or uncontrolled open studies, or extrapolated from other CTD-ILDs of uncertain comparability and therefore inadequate to establish definite recommendations. Robust and well designed randomized controlled clinical trials, possibly stratified by subtype, are needed to evaluate the use of novel therapeutic agents in RA-ILD. Over the next few years, we hope progress will be catalysed by the development of large, multicentre longitudinal patient cohorts and collaborative research efforts. Other potentially interesting future directions include studies of subclinical RA-ILD and biomarker discovery. Addressing the current gaps in knowledge regarding pathogenesis, diagnosis and management of RA-ILD could substantially improve the lives of the not inconsiderable numbers of patients with this debilitating condition.

Footnotes

Acknowledgements

With thanks to all members of the BRILL network. The authors had no assistance with the preparation of this manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Conflict of interest statement

The authors declare that there is no conflict of interest.

References

Agusti

Xaubet

Roca

Agusti

Rodriguez-Roisin

(1992) Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up. Thorax 47: 1035–1040.

Airo

Danieli

Rossi

Frassi

Cavazzana

Scarsi

. (2007) Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 25: 293–296.

American Thoracic Society/European Respiratory Society (2002) American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Resp Crit Care Med 165: 277–304.

Antoniou

Mamoulaki

Malagari

Kritikos

Bouros

Siafakas

. (2007) Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 25: 23–28.

Assayag

Elicker

Urbania

Colby

Kang

Ryu

. (2014) Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 270: 583–588.

Atkins

Turesson

Myers

Tazelaar

Ryu

Matteson

. (2006) Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis–associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 54: 635–641.

Aubart

Crestani

Nicaise-Roland

Tubach

Bollet

Dawidowicz

. (2011) High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 38: 979–982.

Ayhan-Ardic

Oken

Yorgancioglu

Ustun

Gokharman

(2006) Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol 25: 213–218.

Bargagli

Galeazzi

Rottoli

(2004) Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Resp J 24: 708.

10.

Barskova

Gargani

Guiducci

Randone

Bruni

Carnesecchi

. (2013) Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Ann Rheum Dis 72: 390–395.

11.

Bartels

Bell

Shinki

Rosenthal

Bridges

(2010) Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. Rheumatology (Oxford) 49: 1670–1675.

12.

Becerra

Cambridge

(2013) Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement. Ann Rheum Dis 72 450.

13.

Biederer

Schnabel

Muhle

Gross

Heller

Reuter

(2004) Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol 14: 272–280.

14.

Bonella

Costabel

(2014) Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 35: 181–200.

15.

Bongartz

Cantaert

Atkins

Harle

Myers

Turesson

. (2007) Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 46: 70–75.

16.

Bongartz

Nannini

Medina-Velasquez

Achenbach

Crowson

Ryu

. (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62: 1583–1591.

17.

Bosello

De Luca

Rucco

Berardi

Falcione

Danza

. (2015) Long-Term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 44: 428–436.

18.

Braun-Moscovici

Butbul-Aviel

Guralnik

Toledano

Markovits

Rozin

. (2013) Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatology Int 33: 1495–1504.

19.

Brown

(2007) Rheumatoid lung disease. Proc Am Thorac Soc 4: 443–448.

20.

Cavagna

Monti

Grosso

Boffini

Scorletti

Crepaldi

. (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. BioMed Res Int 2013: 13.

21.

Chan

Chapman

Kelly

(2013) Interstitial lung disease in rheumatoid arthritis: a review. Arthritis Research Topical Reviews Series 7: 1–4.

22.

Charles

Sweatman

Markwick

Maini

(1991) Hla-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers 9: 97–101.

23.

Chen

Doyle

Liu

Aggarwal

Wang

Shi

. (2015) Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 67: 28–38.

24.

Chikura

Sathi

Lane

Dawson

(2008) Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology 47: 1647–1650.

25.

Clozel

Salloukh

(2005) Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 37: 2–12.

26.

Cogliati

Antivalle

Torzillo

Birocchi

Norsa

Bianco

. (2014) Standard and pocket-size lung ultrasound devices can detect interstitial lung disease in rheumatoid arthritis patients. Rheumatology (Oxford) 53: 1497–1503.

27.

Conway

Low

Coughlan

O’Donnell

Carey

(2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66: 803–812.

28.

Cottin

(2013) The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 14(Suppl. 1): S5.

29.

Daniels

Lasky

Limper

Mieras

Gabor

Schroeder

(2010) Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 181: 604–610.

30.

Daoussis

Liossis

Tsamandas

Kalogeropoulou

Kazantzi

Sirinian

. (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49: 271–280.

31.

Daoussis

Liossis

Tsamandas

Kalogeropoulou

Paliogianni

Sirinian

. (2012) Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 30: S17–S22.

32.

Dascalu

Mrejen-Shakin

Bandagi

(2010) Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol 16: 172–174.

33.

Dass

Atzeni

Vital

Bingham

Buch

Beirne

. (2011) Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. Ann Rheum Dis 70: 71.

34.

Dawson

Fewins

Desmond

Lynch

Graham

(2001) Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56: 622–627.

35.

Dawson

Fewins

Desmond

Lynch

Graham

(2002) Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 61: 517–521.

36.

Delle Sedie

Doveri

Frassi

Gargani

D’Errico

Pepe

. (2010) Ultrasound lung comets in systemic sclerosis: a useful tool to detect lung interstitial fibrosis. Clin Exp Rheumatol 28: S54.

37.

Demedts

Behr

Buhl

Costabel

Dekhuijzen

Jansen

. (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229–2242.

38.

Dhooria

Agarwal

Gupta

(2015) Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases? Lung India 32: 4–5.

39.

Dias

Pereira

Baldi

Costa

Athanazio

Kairalla

. (2014) Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. J Bras Pneumol 40: 77–81.

40.

Dixon

Abrahamowicz

Beauchamp

Ray

Bernatsky

Suissa

. (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis 71: 851–857.

41.

Dixon

Hyrich

Watson

Lunt

Symmons

(2010) Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 69: 1086–1091.

42.

Doyle

Lee

Dellaripa

Lederer

Matteson

Fischer

. (2014) A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest 145: 454–463.

43.

Doyle

Patel

Hatabu

Nishino

Osorio

. (2015) Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Resp Crit Care Med 191: 1403–1412.

44.

Eyre

Bowes

Diogo

Lee

Barton

Martin

. (2012) High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44: 1336–1340.

45.

Fingerlin

Murphy

Zhang

Peljto

Brown

Steele

. (2013) Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 45: 613–620.

46.

Fischer

Brown

Du Bois

Frankel

Cosgrove

Fernandez-Perez

. (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40: 640–646.

47.

Fischer

Solomon

Du Bois

Deane

Olson

Fernandez-Perez

. (2012) Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Resp Med 106: 1040–1047.

48.

Flaherty

Colby

Travis

Toews

Mumford

Murray

. (2003) Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular Disease. Am J Respir Crit Care Med 167: 1410–1415.

49.

Furukawa

Oka

Shimada

Rheumatoid Arthritis-Interstitial Lung Disease Study Consortium, Tsuchiya

Tohma

(2013) HlA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Ann Rheum Dis 72: 153–155.

50.

Furukawa

Oka

Shimada

Sugii

Ohashi

Matsui

. (2012) Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope. PLoS ONE 7: e33133.

51.

Furuya

Kuwana

(2011) Effect of bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. J Rheumatol 38: 2186–2192.

52.

Gabbay

Tarala

Will

Carroll

Adler

Cameron

. (1997) Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156: 528–535.

53.

Gaffo

Alarcón

(2008) Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168: 1927–1928.

54.

Giles

Danoff

Sokolove

Wagner

Winchester

Pappas

. (2014) Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 73: 1487–1494.

55.

Gizinski

Mascolo

Loucks

Kervitsky

Meehan

Brown

. (2009) Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 28: 611–613.

56.

Glaspole

Hoy

Ryan

(2013) A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford) 52: 2302–2304.

57.

Gochuico

Avila

Chow

Novero

Ren

. (2008) Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168: 159–166.

58.

Goh

Desai

Veeraraghavan

Hansell

Copley

Maher

. (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177: 1248–1254.

59.

Habib

Eisa

Arafat

Marie

(2011) Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol 30: 217–221.

60.

Hadjinicolaou

Nisar

Bhagat

Parfrey

Chilvers

Ostor

(2011) Non-infectious pulmonary complications of newer biological agents for rheumatic diseases–a systematic literature review. Rheumatology (Oxford) 50: 2297–2305.

61.

Hadjinicolaou

Nisar

Parfrey

Chilvers

Östör

(2012) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology 51: 653–662.

62.

Hagiwara

Sato

Takagi-Kobayashi

Hasegawa

Shigihara

Akiyama

(2007) Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 34: 1151–1154.

63.

Hamblin

Horton

(2011) Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulmon Med 2011: 1–12.

64.

Harlow

Rosas

Gochuico

Mikuls

Dellaripa

Oddis

. (2013) Identification of citrullinated HSP90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 65: 869–879.

65.

Haroon

McLaughlin

Henry

Harney

(2011) Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 5: 299–304.

66.

Hartung

Maier

Pfeifer

Fleck

(2012) Effective treatment of rheumatoid arthritis-associated interstitial lung disease by B-cell targeted therapy with rituximab. Case Reports Immunol 2012: 272303.

67.

Herrinton

Harrold

Liu

Raebel

Taharka

Winthrop

. (2013) Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf 22: 394–402.

68.

Horai

Miyamura

Shimada

Takahama

Minami

Yamamoto

. (2012) Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther 37: 117–121.

69.

Hubbard

Venn

(2002) The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 41: 676–679.

70.

Hunninghake

Zimmerman

Schwartz

King

Lynch

Hegele

. (2001) Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 164: 193–196.

71.

Hyeon Ju

Kim

Lee

Yoo

Choe

. (2007) Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 56: 2094–2096.

72.

Inokuma

(2011) Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. Exp Opin Drug Saf 10: 603–611.

73.

Inui

Enomoto

Suda

Kageyama

Watanabe

Chida

(2008) Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 41: 1074–1077.

74.

Jani

Hirani

Matteson

Dixon

(2014) The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 10: 284–294.

75.

Johkoh

Muller

Cartier

Kavanagh

Hartman

Akira

. (1999) Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 211: 555–560.

76.

Kabia

Md Yusof

Dass

Vital

Beirne

Emery

(2015) Efficacy and safety of rituximab in rheumatoid arthritis patients with concomitant interstitial lung disease: 10-year experience at single centre. Rheumatology 54: i86.

77.

Kamata

Nara

Kamimura

Haneda

Iwamoto

Masuyama

. (2004) Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43: 1201–1204.

78.

Kawashiri

Kawakami

Sakamoto

Ishimatsu

Eguchi

(2012) A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 32: 4023–4026.

79.

Kelly

Chan

Nisar

Arthanari

Woodhead

Dawson

. (2013) Fri0114 rheumatoid arthritis related interstitial lung disease – relevance of lung function tests and high resolution computed tomography in a large multi centre series. Ann Rheum Dis 72: A408–A409.

80.

Kelly

Saravanan

(2008) Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Exp Opin Pharmacother 9: 3221–3230.

81.

Kelly

Saravanan

Nisar

Arthanari

Woodhead

Price-Forbes

. (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology 53: 1676–1682.

82.

Khanna

Saggar

Mayes

Abtin

Clements

Maranian

. (2011) A one-year, phase I/IIA, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 63: 3540–3546.

83.

Kim

Collard

King

(2009) Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 136: 1397–1405.

84.

Kim

Elicker

Maldonado

Webb

Ryu

Van Uden

. (2010) Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Resp J 35: 1322–1328.

85.

King

Jr Behr

Brown

Du Bois

Lancaster

De Andrade

. (2008) Build-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177: 75–81.

86.

King

Jr Bradford

Castro-Bernardini

Fagan

Glaspole

Glassberg

. (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370: 2083–2092.

87.

King

Jr Brown

Raghu

Du Bois

Lynch

Martinez

. (2011) Build-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184: 92–99.

88.

Kinoshita

Hamano

Harada

Kinoshita

Igishi

Hagino

. (2004) Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 98: 1131–1137.

89.

Klareskog

Stolt

Lundberg

Källberg

Bengtsson

Grunewald

. (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54: 38–46.

90.

Kocheril

Appleton

Somers

Kazerooni

Flaherty

Martinez

. (2005) Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 53: 549–557.

91.

Koduri

Norton

Young

Cox

Davies

Devlin

. (2010) Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 49: 1483–1489.

92.

Koike

Harigai

Inokuma

Inoue

Ishiguro

Ryu

. (2009) Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36: 898–906.

93.

Koike

Harigai

Ishiguro

Inokuma

Takei

Takeuchi

. (2012) Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Modern Rheumatol 22: 498–508.

94.

Komiya

Ishii

Fujita

Oka

Iwata

Sonoda

. (2011) Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement. Intern Med 50: 749–751.

95.

Kozo

Yasunari

Tsukasa

Tomoya

Haruhiko

Kimitake

. (2013) Proteomics analysis of BALF in rheumatoid arthritis associated interstitial lung disease with usual interstitial pneumonia pattern, B67. Insights into Fibrosis from Translational Studies. Proc Am Thorac Soc 3: 467–471.

96.

Kubo

Nakayama

Yanai

Suzuki

Yamaya

Watanabe

. (2005) Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128: 1475–1482.

97.

Lager

Hilberg

Lokke

Bendstrup

(2013) Severe interstitial lung disease following treatment with certolizumab pegol: a case report. Eur Respir Rev 22: 414–416.

98.

Lake

Proudman

(2014) Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med 35: 222–238.

99.

Lee

Kim

Yoo

Seo

Rho

Colby

. (2005) Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127: 2019–2027.

100.

Legg

(2010) Connective tissue diseases: bosentan treatment unable to alter the progression of interstitial lung disease in patients with SSC. Nat Rev Rheumatol 6: 309–309.

101.

Lindsay

Melsom

Jacob

Mestry

(2006) Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 45: 1048–1049.

102.

Lioté

Séroussi

Mayaud

Cadranel

(2010) Rituximab-induced lung disease: a systematic literature review. Eur Resp J 35: 681–687.

103.

Makrygiannakis

Hermansson

Ulfgren

Nicholas

Zendman

Eklund

. (2008) Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 67: 1488–1492.

104.

Martin

Innes

Lambert

Turnbull

Wallace

(2007) Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 34: 1934–1937.

105.

Matteson

Bongartz

Ryu

Crowson

Hartman

Dellaripa

(2012) Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis 2: 53–58.

106.

Mazzei

Richeldi

Collard

(2015) Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 9: 121–129.

107.

McGonagle

Tan

Madden

Rawstron

Rehman

Emery

. (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 47: 552–553.

108.

Mera-Varela

Perez-Pampin

(2014) Abatacept therapy in rheumatoid arthritis with interstitial lung disease. J Clin Rheumatol 20: 445–446.

109.

Michalski

McCombs

Scopelitis

Biundo

Jr Medsger

Jr (1986) Alpha1-antitrypsin phenotypes, including m subtypes, in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis. Arthritis Rheum 29: 586–591.

110.

Migita

Nakamura

Koga

Eguchi

(2010) HLA-DRB1 alleles and rheumatoid arthritis-related pulmonary fibrosis. J Rheumatol 37: 205–207.

111.

Min

Lee

Lim

Ahn

Park

Chung

. (2011) Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 68: 1099–1109.

112.

Mink

Maycher

(2012) Comparative manifestations and diagnostic accuracy of high-resolution computed tomography in usual interstitial pneumonia and nonspecific interstitial pneumonia. Curr Opin Pulm Med 18: 530–534.

113.

Miura

Saito

Fujita

Tanaka

Tsunoda

Azuma

. (2014) Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 31: 235–238.

114.

Moazedi-Fuerst

Kielhauser

Brickmann

Tripolt

Meilinger

Lufti

. (2015) Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. Clin Exp Rheumatol 33(Suppl. 91): S87–S91.

115.

Moazedi-Fuerst

Kielhauser

Scheidl

Tripolt

Lutfi

Yazdani-Biuki

. (2014) Ultrasound screening for interstitial lung disease in rheumatoid arthritis. Clin Exp Rheumatol 32: 199–203.

116.

Mohr

Jacobi

(2011) Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol 40: 400–401.

117.

Mori

Imamura

Kiyofuji

Sugimoto

(2006) Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol 16: 251–255.

118.

Mori

Koga

Sugimoto

(2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Resp Med 106: 1591–1599.

119.

Nagai

Hamada

Shigematsu

Taniyama

Yamauchi

Izumi

(2002) Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41: 1118–1123.

120.

Nakamura

Suda

Kaida

Kono

Hozumi

Hashimoto

. (2012) Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. Resp Med 106: 1164–1169.

121.

Nakashita

Ando

Kaneko

Takahashi

Motojima

(2014) Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open 4: e005615.

122.

Nannini

West

Erwin

Matteson

(2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10: R124.

123.

National Institute for Health and Care Excellence (2009) Rheumatoid Arthritis: The Management of Rheumatoid Arthritis in Adults. London: NICE.

124.

National Institute of Health and Care Excellence (2013) Pirfenidone for Treating Idiopathic Pulmonary Fibrosis. NICE technology appraisal guidance TA282. London: NICE

125.

Noth

Anstrom

Calvert

De Andrade

Flaherty

Glazer

. (2012) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186: 88–95.

126.

O’Dwyer

Armstrong

Cooke

Dodd

Veale

Donnelly

(2013) Rheumatoid arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med 24: 597–603.

127.

Oka

Furukawa

Shimada

Hayakawa

Fukui

Tsuchiya

. (2013) Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease. BMC Immunol 14: 9.

128.

Okada

Trynka

Raj

Terao

Ikari

. (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506: 376–381.

129.

Olivas-Flores

Bonilla-Lara

Gamez-Nava

Rocha-Muñoz

Gonzalez-Lopez

(2015) Interstitial lung disease in rheumatoid arthritis: current concepts in pathogenesis, diagnosis and therapeutics. World J Rheumatol 5: 1–22.

130.

Ostor

Chilvers

Somerville

Lim

Lane

Crisp

. (2006) Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 33: 622–628.

131.

Panopoulos

Sfikakis

(2011) Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulmon Med 17: 362–367.

132.

Park

Kim

Park

Jang

Kitaichi

Nicholson

. (2007) Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175: 705–711.

133.

Pearce

Johnson

Courtney

(2012) Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford) 51: 578–580.

134.

Perez-Alvarez

Perez-De-Lis

Diaz-Lagares

Pego-Reigosa

Retamozo

Bove

. (2011) Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 41: 256–264.

135.

Raghu

Anstrom

King

Jr Lasky

Martinez

(2012) Prednisone, azathioprine, and n-acetylcysteine for pulmonary fibrosis. N Engl J Med 366: 1968–1977.

136.

Raghu

Depaso

Cain

Hammar

Wetzel

Dreis

. (1991) Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144: 291–296.

137.

Rajasekaran

Shovlin

Saravanan

Lord

Kelly

(2006) Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol 33: 1250–1253.

138.

Ramos-Casals

Brito-Zeron

Munoz

Soria

Galiana

Bertolaccini

. (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242–251.

139.

Richardson

Singer

(2014) Lung transplantation for scleroderma-related lung disease. Curr Resp Care Rep 3: 79–87.

140.

Richeldi

(2013) Clinical trials of investigational agents for IPF: a review of a Cochrane report. Respir Res 14(Suppl. 1): S4.

141.

Richeldi

Costabel

Selman

Kim

Hansell

Nicholson

. (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365: 1079–1087.

142.

Richeldi

Du Bois

Raghu

Azuma

Brown

Costabel

. (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370: 2071–2082.

143.

Richman

Yazdany

Graf

Chernitskiy

Imboden

(2013) Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine 92: 92–97.

144.

Romero

Recuero

Gomez-Seco

Rodriguez-Nieto

Presa

Mahillo

. (2013) Safety and clinical response to rituximab in patients with connective tissue disease-associated interstitial lung disease: preliminary results. Ann Rheum Dis 71: 1496–1499.

145.

Rosas

Richards

Konishi

Zhang

Gibson

Lokshin

. (2008) MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 5: e93.

146.

Roubille

Haraoui

(2014) Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43: 613–626.

147.

Saag

Kolluri

Koehnke

Georgou

Rachow

Hunninghake

. (1996) Rheumatoid arthritis lung disease. determinants of radiographic and physiologic abnormalities. Arthritis Rheum 39: 1711–1719.

148.

Sabnani

Zucker

Rosenstein

Baran

Arroyo

Tsang

. (2009) A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology 48: 49–52.

149.

Saketkoo

Espinoza

(2008) Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 168: 1718–1719.

150.

Saketkoo

Espinoza

(2009) Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 337: 329–335.

151.

Salliot

Van Der Heijde

(2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68: 1100–1104.

152.

Sathi

Chikura

Kaushik

Wiswell

Dawson

(2012) How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol 31: 79–83.

153.

Sathi

Urwin

Desmond

Dawson

(2011) Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease. Rheumatology 50: 620.

154.

Savage

Highton

Boyd

Chapman

(2006) Pneumonitis associated with leflunomide: a profile of New Zealand and Australian Reports. Intern Med J 36: 162–169.

155.

Sawada

Inokuma

Sato

Otsuka

Saeki

Takeuchi

. (2009) Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 48: 1069–1072.

156.

Schachna

Medsger

Jr Dauber

Wigley

Braunstein

White

. (2006) Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 54: 3954–3961.

157.

Schoe

Van Der Laan-Baalbergen

Huizinga

Breedveld

Van Laar

(2006) Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 55: 157–159.

158.

Schwarz

King

(2010) Interstitial Lung Disease. People’s Medical Publishing House. Available at: www.axon.es/Axon/LibroFicha.asp?Libro=81891

159.

Seibold

Denton

Furst

Guillevin

Rubin

Wells

. (2010) Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 62: 2101–2108.

160.

Sharyn

Michael

David

Susan

Sujal

Roland

. (2001) Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 221: 600–605.

161.

Silva

Muller

Hansell

Lee

Nicholson

Wells

(2008) Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology 247: 251–259.

162.

Song

Lee

Chae

Jang

Colby

. (2013) Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 30: 103–112.

163.

Soubrier

Jeannin

Kemeny

Tournadre

Caillot

Caillaud

. (2008) Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 75: 362–365.

164.

Spagnolo

Grunewald

Du Bois

(2014) Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Resp Med 2: 416–428.

165.

Sperandeo

Varriale

Sperandeo

Filabozzi

Piattelli

Carnevale

. (2009) Transthoracic ultrasound in the evaluation of pulmonary fibrosis: our experience. Ultrasound Med Biol 35: 723–729.

166.

Stahl

Raychaudhuri

Remmers

Xie

Eyre

Thomson

. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42: 508–514.

167.

Sugiyama

Ohno

Kano

Maeda

Kitamura

(1994) Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern Med 33: 612–614.

168.

Suissa

Hudson

Ernst

(2006) Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 54: 1435–1439.

169.

Sumida

Asano

Tamaki

Aozasa

Taniguchi

Takahashi

. (2014) Successful Experience of Rituximab Therapy for Systemic Sclerosis-Associated Interstitial Lung Disease with Concomitant Systemic Lupus Erythematosus. J Dermatol 41: 418–420.

170.

Suwa

Hirakata

Satoh

Mimori

Utsumi

Inada

(1998) Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with IV cyclophosphamide therapy. Clin Exp Rheumatol 17: 355–358.

171.

Swigris

Olson

Fischer

Lynch

Cosgrove

Frankel

. (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130: 30–36.

172.

Takeuchi

Tatsuki

Nogami

Ishiguro

Tanaka

Yamanaka

. (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189–194.

173.

Taki

Kawagishi

Shinoda

Hounoki

Ogawa

Sugiyama

. (2009) Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int 30: 275–276.

174.

Tanaka

Kim

Newell

Brown

Cool

Meehan

. (2004) Rheumatoid arthritis-related lung diseases: CT findings. Radiology 232: 81–91.

175.

Tardella

Gutierrez

Salaffi

Carotti

Ariani

Bertolazzi

. (2012) Ultrasound in the assessment of pulmonary fibrosis in connective tissue disorders: correlation with high-resolution computed tomography. J Rheumatol 39: 1641–1647.

176.

Tashkin

Elashoff

Clements

Goldin

Roth

Furst

. (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354: 2655–2666.

177.

Tashkin

Elashoff

Clements

Roth

Furst

Silver

. (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176: 1026–1034.

178.

The Idiopathic Pulmonary Fibrosis Clinical Research Network (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370: 2093–2101.

179.

Tournadre

Ledoux-Eberst

Poujol

Dubost

J.J.

Ristori

J.M.

Soubrier

(2008) Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine 75: 215–218.

180.

Tsuchiya

Takayanagi

Sugiura

Miyahara

Tokunaga

Kawabata

. (2011) Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37: 1411–1417.

181.

Turesson

Jacobsson

Sturfelt

Matteson

Mathsson

Ronnelid

(2007) Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66: 59–64.

182.

Tzouvelekis

Galanopoulos

Bouros

Kolios

Zacharis

Ntolios

. (2012) Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012: 7.

183.

Udwadia

Mullerpattan

Balakrishnan

Richeldi

(2015) Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India 32: 50–52.

184.

Vassallo

Matteson

Thomas

Jr (2002) Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-α inhibition. Chest 122: 1093–1096.

185.

Wada

Akiyama

Yokota

Sato

Funakubo

Mimura

(2012) [A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept]. Nihon Rinsho Meneki Gakkai Kaishi 35: 433–438.

186.

Wang

Ding

(2011) Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Case Rep 4: 49–52.

187.

Wells

Hirani

(2008) Interstitial lung disease guideline. Thorax 63: v1–v58.

188.

Wells

Ward

(2014) Pulmonary function tests in idiopathic pulmonary fibrosis. In: Meyer

Nathan

(eds), Idiopathic Pulmonary Fibrosis, Vol. 9. Humana Press, pp. 103–121. Available at: link.springer.com/content/pdf/10.1007/978-1-62703-682-5_6.pdf

189.

Wendling

Vidon

Godfrin-Valnet

Rival

Guillot

Prati

(2013) Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine 80: 670–671.

190.

Xaubet

Serrano-Mollar

Ancochea

(2014) Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Exp Opin Pharmacother 15: 275–281.

191.

Yamazaki

Isogai

Sakurai

Nagasaka

(2010) A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod Rheumatol 20: 518–521.

192.

Yazdani

Singer

Strand

Gelber

Williams

Mittoo

(2014) Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 33: 514–520.

193.

Yiannopoulos

Pastromas

Antonopoulos

Katsiberis

Kalliolias

Liossis

. (2007) Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27: 357–361.

194.

Yin

Liang

Zhao

Liu

Ren

. (2014) Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One 9: e92449.

195.

Yoo

(2012) Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 32: 795–798.

196.

Yoshinouchi

Ohtsuki

Fujita

Yamadori

Bandoh

Ishida

. (2005) Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 26: 121–125.

197.

Young

Koduri

Batley

Kulinskaya

Gough

Norton

. (2007) Mortality in rheumatoid arthritis. increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46: 350–357.

198.

Ytterberg

Joshua

Reynisdottir

Tarasova

Rutishauser

Ossipova

. (2014) Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis 74: 1772–1777.

199.

Zhu

Zhou

Chen

(2014) A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 41: 1282–1289.

Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review

Abstract

Keywords

Introduction

Histopathological and radiographic classification

Epidemiology

Incidence and prevalence

Mortality and prognosis

Pathogenesis

Diagnosis

Clinical presentation

Pulmonary function tests

Bronchoalveolar lavage

Imaging

Lung biopsy

Ultrasound

Differential diagnosis

Biomarkers

Treatment

Conservative therapy

Immunosuppressive agents

Disease-modifying antirheumatic drugs

Biologic drugs

Antitumour necrosis factor agents

Rituximab

Other agents

Lung transplant

Future directions

Conclusion

Footnotes

Acknowledgements

Funding

Conflict of interest statement

References